1、Table 3Benefit-Risk Analysis of Agents Used to Treat Neuropathic PainMedication Number of Patients Needed to Treat(NNT)for Efficacy/Adverse EffectsPainful/DiabeticNeuropathyPostherpetic NeuralgiaPeripheral Nerve InjuryTrigeminalNeuralgiaTricyclic antidepressants Amitriptyline Desipramine2.4/4.92.0/9
2、.73.4/202.3/62.3/6.2 1.9/4.8 2.5/ND2.5/NDSSRIs Paroxetine Citalopram 6.7/ND2.9/ND7.7/NDPhenytoin 2.1/9.5Carbamazepine 3.3/1.92.6/3.4Gabapentin 3.7/1.83.2/3.4 Lamotrigine 2.1/NDMexiletine 10.0/6.3Baclofen 1.4/NDTramadol 3.4/NDOxycodone 2.5/ND Source:References 15,21,22,26,27,30-32,37 Noradrenaline Glutamate Substance PModulates neurotransmitter release Modulates neurotransmitter release e.g.e.g.PostsynapticPostsynapticNeurotransmitter Binding SitePresynapticPresynapticVoltage-Gated Ca2+channel 2 2 SubunitSubunitNeurotransmitter Transporter设备SCS 植入试验试验试验电极位置上肢上肢 T1-2下腰痛下腰痛 T8-10下肢下肢 T10-12试验试验
